Vertex Pharmaceuticals is reportedly acquiring Crinetics, a company that specializes in endocrine disease drugs, in a $10 billion deal. This acquisition is said to be the largest in Vertex's history and is part of the company's growth strategy. The move appears to be an effort by Vertex to expand its presence in a new area of biotech.